Mirikizumab-Mrkz 100 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 100 mg

Reference Brands: Omvoh (USA)

Category: Immune Disorder

Mirikizumab 100 mg subcutaneous injection, an anti-IL-23 p19 monoclonal antibody for maintenance therapy in ulcerative colitis and Crohn's disease. For hospital and specialty pharmacy buyers with cold chain.

Product Description:

Mirikizumab is a humanised IgG4 monoclonal antibody that binds the p19 subunit of interleukin-23. IL-23 drives a pathway of gut inflammation, and blocking p19 targets it without touching IL-12. The -mrkz ending is the four-letter suffix the US FDA adds to biological names. This page covers the 100 mg subcutaneous injection in a single-dose prefilled pen, used for maintenance. Induction uses a separate 300 mg intravenous vial, and a 200 mg pen exists for Crohn's disease.

It is used in adults with moderately to severely active ulcerative colitis and, where approved, Crohn's disease, after inadequate response, loss of response or intolerance to conventional or biologic therapy. In ulcerative colitis, maintenance is two 100 mg injections every four weeks after intravenous induction. Patients are screened for tuberculosis first, and serious infections need watching. Liver enzymes and bilirubin are checked at baseline and during induction, as liver injury has been reported. Live vaccines should be avoided.

Sourcing notes. Mirikizumab is a recent biological medicine, so supply runs through the originator's registered product and its national authorisations. Confirm that the pack offered is registered in your market and labelled in the local language. Cold chain is essential: 2-8 °C, in the carton away from light, never frozen. Request shipping validation and logger records, a CoA and batch release papers, the finished-product GMP certificate and a CoPP. It is prescription-only, dispensed through specialist gastroenterology services. Name the presentation, quantity, minimum shelf life and delivery point.